阿帕替尼治疗耐铂型卵巢癌短期疗效与安全性观察

目的:探讨阿帕替尼治疗耐铂型卵巢癌的短期疗效与安全性。方法:收集2015年7月2019年1月在郑州大学第一附属医院治疗的耐铂型卵巢癌患者,根据治疗方案分为2组:单纯化疗组(吉西他滨+奥沙利铂)和阿帕替尼联合化疗组(阿帕替尼+吉西他滨+奥沙利铂)。评价2组患者的客观缓解率(ORR)和疾病控制率(DCR),并比较2组的不良反应发生率。结果:阿帕替尼联合化疗组的ORR(52.4%vs.24.0%)及DCR(61.9%vs.32.0%)均优于单纯化疗组,且治疗后CA125水平明显低于单纯化疗组,差异均有统计学意义(P<0.05)。阿帕替尼联合化疗组的高血压、手足皮肤反应发生率较单纯化疗组高(P<0.05),所有不良反应对症支持治疗后均可缓解。结论:阿帕替尼联合化疗治疗耐铂型卵巢癌安全有效。

Short-Term Efficacy and Safety of Apatinib in the Treatment of Platinum-Resistant Ovarian Cancer

Objective:To explore the short-term efficacy and safety of apatinib in the treatment of platinum-resistant ovarian cancer.Methods:Patients with platinum-resistant ovarian cancer treated at the First Affiliated Hospital of Zhengzhou University from July 2015 to January 2019 were collected and divided into 2 groups according to the treatment protocol:simple chemotherapy group(gemcitabine+oxaliplatin)and apatinib combined chemotherapy group(apatinib+gemcitabine+oxaliplatin).The objective remission rate(ORR)and disease control rate(DCR)were evaluated and the incidence of adverse reactions was compared in the 2 groups.Results:The ORR(52.4%vs.24.0%)and DCR(61.9%vs.32.0%)in the apatinib combined chemotherapy group were better than those in the simple chemotherapy group,and the level of CA125 after treatment was significantly lower than that in the simple chemotherapy group(P<0.05).The incidence of hypertension and skin reaction of hand and foot in the apatinib combined chemotherapy group was higher than that in the simple chemotherapy group(P<0.05),and all adverse reactions could be alleviated after symptomatic support treatment.Conclusions:Apaintib combined with chemotherapy is effective and safe in treating platinum-resistant ovarian cancer.